FOLDABLE CAPSULAR VITREOUS BODY IMPLANTATION FOR COMPLICATED RETINAL DETACHMENT CAUSED BY SEVERE OCULAR TRAUMA

MEILI LI, MD,* YU TANG, BD,† SUYAN LI, MD,* ZHENGPEI ZHANG, MD,* LINA GUAN, MD,* JIE LI, MD,* JING XU, BD,* SUJUAN JI, MD*

Purpose: To explore the effectiveness, safety and psychological impact of foldable capsular vitreous body (FCVB) implantation for complicated retinal detachment caused by severe ocular trauma.

Methods: This was a prospective, single-arm, surgical interventional case series study. A standard 3-port 23-gauge pars plana vitrectomy was performed, and the FCVB was implanted into the vitreous cavity. Observed indicators, including the best-corrected visual acuity, intraocular pressure (IOP), retinal reattachment, complications, and patient satisfaction, were analyzed to evaluate the study.

Results: A total of 28 cases (eyes) were enrolled, with a mean follow-up of 16.93 ± 9.67 months and an average age of 51.11 ± 10.14 years, including 22 men (78.57%). The FCVB was successfully implanted, and the retina was reattached in all cases. The postoperative best-corrected visual acuity improved in 7 cases, and remained unchanged in 21 cases ($P < 0.05$). The average IOP was 7.01 ± 2.43 mmHg before surgery and 8.54 ± 2.93 mmHg after surgery ($P < 0.05$). Complications such as FCVB displacement, endophthalmitis, secondary glaucoma, silicone oil emulsification, and escape did not occur during the follow-up period. Patients with FCVB implantation are highly satisfied. Most patients feel hope, positive, and optimistic about life.

Conclusion: Foldable capsular vitreous body implantation for complicated retinal detachment caused by severe ocular trauma is effective and safe, and it allows patients to face life positively and optimistically.

RETINA 42:1512–1519, 2022

Severe ocular trauma is one of the causes of monocular blindness, which can not only cause a serious decline in the quality of life, but also affect appearance and thus affect the mental health of patients. The etiologies and complications of ocular injuries vary. Severe ocular trauma includes penetrating eye injury, rupture of the eyeball, complicated retinal detachment, retinal defect, choroidal detachment, and suprachoroidal and vitreous hemorrhage. The first-line treatment was to perform eye repair surgery, and the second-line traditional treatment was to choose pars plana vitrectomy (PPV) combined with silicone oil filling or to give up surgery. In the former patient, this may eventually cause silicone oil dependence and produce various complications, such as intraocular hypertension, corneal degeneration, retinal redetachment, and silicone oil emulsification. Patients who are not suitable for PPV or give up surgery will eventually experience atrophy of the eyeball, which affects appearance. Further negative psychological problems, such as low self-esteem, pessimism, and depression, will occur.

For patients with severe visual impairment or complicated conditions that are not suitable for posterior approach PPV combined with silicone oil filling surgery, if we can find a way to support the shape of the eyeball and keep the appearance basically normal or even preserve part of the vision, the psychological problems caused by appearance can be avoided. Foldable capsular vitreous body (FCVB) uses a modified polysiloxane elastomer as the basic material for preparing film pouches; the material becomes elastically deformed; has good tensile, physical, and mechanical properties; and low hardness. Compared
with the direct injection of silicone oil into the vitreous cavity, FCVB avoids the direct contact of silicone oil with the intraocular tissues, which prolongs the retention time in the eye, reduces related complications caused by silicone oil, and does not require a second oil extraction operation. As a result, FCVB can be placed in the eye for a long time. We implanted FCVB into the vitreous cavity after PPV to study the effectiveness, safety, and psychological impact in the treatment of complicated retinal detachment caused by severe ocular trauma.

Methods

Ethical Standards

The study was approved by the Ethics Committee of Xuzhou First People’s Hospital. The research process followed the Declaration of Helsinki.

Patients

From October 2018 to August 2021, patients treated with FCVB in Xuzhou First People’s Hospital were enrolled in this prospective, single-arm, surgical interventional case series study. We first selected patients with complicated retinal detachment caused by severe eye trauma (Figure 1). Second, the best-corrected visual acuity (BCVA) of these patients must be so poor that they can only recognize hand move (HM), light perception (LP), or no light perception (NLP). Third, the axial length (AL) of the injured eye was between 16 and 28 mm. In addition, patients with severe systemic diseases who could not tolerate surgery, patients who were allergic to silicone, patients with serious eye inflammation or endophthalmitis, and patients whose fundus could not be observed because of corneal opacity were excluded. Patients found to be treatable with silicone oil during surgery were also excluded. All patients approved the surgery in written form after being explained the risks and complications in detail.

Surgical Procedure

The operations were performed by the same surgeon, who had more than 10 years of experience in PPV. Before the surgery, A-scan ultrasound or orbital computed tomography was performed to estimate the AL, which helped us choose the size of the FCVB. The right eye was taken as an example. The patients were placed in the supine position. After retrobulbar anesthesia, a gas–liquid exchange was performed. The vitreous hemorrhage and proliferation membrane were peeled off and cut clean. If necessary, heavy water was injected to flatten the retina, and a laser was used to conglutinate the retina and choroid. The lens capsule was removed and an iris hole was made in the subnasal position. Gas–liquid exchange was performed, and the air pressure was increased to 50 to 60 mmHg to reduce bleeding. After cutting and detaching the supratemporal bulbar conjunctiva, a scleral incision was made and expanded to 4 mm parallel to the limbus at a location 5 mm behind the limbus. The FCVB was checked for leaks by injecting with air and then putting it into the water (Figure 2). After folding by an assistant, the FCVB was placed in the injector and sent putting it into the water (Figure 2). After folding by an assistant, the FCVB was placed in the injector and sent into the vitreous cavity perpendicular to the sclera from the expanded puncture. The scleral incision was sutured with an 8-0 absorbable suture to stabilize the intraocular pressure (IOP). According to the FCVB size, a suitable volume of silicone oil (viscosity was 5,000 mpa.s) was slowly injected into the capsule. It should be noted that, as the capsule was unfolded, the trocars were gradually removed to avoid puncturing it. Viscoelastics were...
injected into the anterior and posterior chambers to maintain intraocular pressure and eyeball shape. A simple applanation tonometer can be used to measure intraocular pressure during the operation. After adjusting the position of the FCVB, the tube was ligated with 5-0 nonabsorbable sutures, and the valve was fixed to the scleral surface. The fascia, bulbar conjunctiva, and punctures were sutured separately with 8-0 absorbable sutures (Figure 3; see Video, Supplemental Digital Content 1, http://links.lww.com/IAE/B701).

**Follow-Up Strategy and Observed Indicators**

Close observation and follow-up are necessary within the first month after surgery, especially the first week. Regular follow-up was conducted at 1, 3, and 6 months postoperatively and then every 6 months until loss. A minimum of 1 year of follow-up was required for the patients.

The postoperative effectiveness of FCVB implantation was evaluated by observed indicators at the last follow-up, including BCVA, IOP (with Goldmann applanation tonometry, GAT), retinal reattachment and FCVB position (with B-scan ultrasound and fundus photography), shape of the eyeball (with slit lamp biomicroscopy), and facial appearance (with facial photography). Complications during and after surgery were recorded to assess the safety of FCVB implantation.

Patient satisfaction with treatment outcomes and feelings was graded according to the following system: feel dissatisfied as 0, feel satisfied sometime as 1, feel satisfied most of the time as 2, and feel satisfied all the time as 3.
Statistical Analysis

Statistical analysis was performed by SAS v9.02 software (SAS Institute Inc, Cary, NC). Continuous data were described as the mean ± SD, and categorical data were described as percentages. Continuous data were compared using Student’s t test. Categorical data were compared by the chi-square test (Cochran-Mantel-Hanenszel, CMH). \( P < 0.05 \) was considered significant.

Results

Baseline Data

A total of 28 cases (eyes) were enrolled, with a mean follow-up of 16.93 ± 9.67 months (range from 6 to 36 months). There were 22 men (78.57%) and 6 women (21.43%), with an average age of 51.11 ± 10.14 years. The age range was between 31 and 71 years old. There were 14 cases in the right eye (50%) and 14 cases in the left eye (50%). Metal accounted for 35.71% of the causes of ocular trauma, as shown in Table 1, followed by fist, wood, and traffic accidents. In addition, 2 cases with eyeball atrophy were waiting for surgery for 1 year after ocular trauma, 3 cases for two months, and 23 cases within one month after primary suture.

Evaluation of the Effectiveness

Most patients maintained their preoperative vision after surgery. Postoperative BCVA improved in 7 cases compared with preoperative, BCVA remained unchanged in 21 cases (we found that there was no difference between BCVA and naked vision). The results are shown in Table 2. There was no statistically significant difference between postoperative and preoperative BCVA (\( P > 0.05 \)). The average IOP was 7.01 ± 2.43 mmHg before surgery and 8.54 ± 2.93 mmHg after surgery, and the difference was statistically significant (\( P < 0.05 \)). During the follow-up period of all cases, the FCVB was intact and well positioned, the retina was reattached, the shape of the eyeball in all cases was maintained well, and the appearance did not seem to be significantly different from the contralateral eye (Figure 1).

Evaluation of Safety

The retina was reattached in all cases during the operation, and the FCVB was also successfully implanted in the vitreous cavity in all cases. There was no massive bleeding or FCVB rupture during the operation. In one case, the position of the FCVB was found to be slightly shifted after implantation and returned to normal after adjustment with the iris restorer. Mild inflammation in the anterior chamber was found in 6 cases, which usually disappeared with antiinflammatory treatment approximately 1 month after surgery. In the early postoperative period, 9 patients developed hemorrhage in the anterior chamber, and the bleeding gradually stopped within 3 days after the intravenous infusion of hemostatic drugs. The hemorrhage was absorbed, in 8 cases, one week after the operation and, in 1 case, 3 weeks after the operation. In one case, the IOP temporarily increased to 28 mmHg on the 7th day after surgery and returned to normal after the application of carteolol hydrochloride and brinzolamide eye drops for one week. One case had a shallow anterior chamber, and after performing anterior chamber-plasty on the third day after FCVB surgery, the depth of the anterior chamber returned to normal. One case had valve exposure 3 weeks after surgery, and we placed simple sutures to avoid further complications. Complications such as
rejection, corneal degeneration, FCVB displacement, endophthalmitis, secondary glaucoma, strabismus, silicone oil emulsification, and escape did not occur during the follow-up period.

**Satisfaction Evaluation**

 Conjunctival or scleral hyperemia in all patients disappeared between 1 and 2 months after surgery and did not affect appearance eventually. Some patients had a mild foreign body sensation within 1 month after surgery. No atrophy of the eyeballs occurred. As shown in Table 3, postoperative satisfaction was significantly better than preoperative satisfaction ($P < 0.05$). None of the patients regretted the decision. Most patients felt that life was full of hope, felt positive and optimistic about life, did not worry about others looking at the injured eye, and even took the initiative to introduce the implanted FCVB to their friends.

**Discussion**

For complicated retinal detachment caused by severe ocular trauma, the traditional treatment is to perform PPV, inject silicone oil to fill the vitreous cavity after flattening the retina, and maintain a prone position for more than 3 months after surgery to achieve good pressure on the retina. The intraocular pressure will remain low, and even retinal redetachment will occur after removal of intraocular silicone oil tamponade in some patients. In these cases, another silicone oil filling operation must be performed, which we call silicone oil-dependent eyes. Patients who have undergone one or more surgeries for complicated
retinal detachment, especially those who have used silicone oil, are more likely to develop epiretinal proliferation, which will lead to the final failure of the operation.\textsuperscript{11} Silicone oil will cause a toxic effect on ganglion cells and lead to visual deterioration.\textsuperscript{12} Moreover, silicone oil will emulsify because of direct contact with eye tissue, and the emulsified silicone oil droplets will shift, run into the anterior chamber, cause corneal endothelial damage, block the angle of the chamber (causing secondary glaucoma), and even shift into the brain tissue to cause more serious complications.\textsuperscript{9,13} In addition, if the time is too long from injury or the intraocular structure is severely damaged, patients who are not suitable for PPV will eventually experience atrophy of the eyeball and collapse of the eye socket, affecting facial appearance.

Fortunately, in recent years, a capsular artificial vitreous called FCVB, initially developed independently in China, has been used to replace silicone oil to support the retina.\textsuperscript{14} It is a transparent macromolecule cross-linking polymer of polyvinylsiloxane and polyhydrosiloxane with good mechanical properties and biocompatibility and has been proven to be nontoxic to mouse fibroblast cell lines.\textsuperscript{14} The optical properties of FCVB indicate that transmittances are 92%, hazes are 5.74%, and spectral transmittance is 97%, which reveal that FCVB is a highly transparent material and can meet the requirement of an artificial vitreous body to be transparent. In addition, FCVB can endure a 1,500 mW, 0.2 seconds, 532 nm green laser.\textsuperscript{15} The FCVB has been approved by the Chinese Food and Drug Administration and obtained CE certification for distribution and use in the European Economic Area.\textsuperscript{16} In 2012, FCVB was rated one of four advances in retinal detachment surgery worldwide.\textsuperscript{17} In recent years, FCVB has been increasingly used in clinical treatment. Similar to the results of previous clinical studies,\textsuperscript{18,19} during the follow-up period, all cases in our study achieved retinal reattachment. Although postoperative visual acuity is not significantly improved compared with preoperative visual acuity, intraocular pressure is maintained in a balanced state, which not only preserves preoperative visual acuity but also maintains the shape of the eyeball, which shows that implantation of the FCVB is an effective treatment in eyes with complicated retinal detachment caused by severe ocular trauma.\textsuperscript{20} According to Lin et al.,\textsuperscript{21} IOP and visual acuity did not show a significant difference in FCVB eyes compared with preoperative measurements. The visual acuity and intraocular pressure after FCVB implantation showed a slight elevation compared with those of preoperative eyes in another study.\textsuperscript{22} Although the FCVB has good retinal supporting function, it has a higher incidence of cataracts.\textsuperscript{23} As a result, the lens needs to be removed during the operation.

An experimental study showed that FCVB tamponade in rabbit eyes did not cause retinal vascular pathologic changes or retinal hypoxia.\textsuperscript{24} The FCVB had sufficient porosity to allow cytokines to pass through and favorable permeability of proteins in the human eye.\textsuperscript{25} The change in the density of corneal endothelial cells was not statistically significant in the 12 months after FCVB implantation, and ultrasound biomicroscopy showed that the FCVB smoothly contacted but did not crush the ciliary body.\textsuperscript{22} Compared with directly filling the vitreous cavity with silicone oil, the FCVB avoids direct contact between silicone oil and intraocular tissues and reduces related complications caused by silicone oil. The FCVB was

| Table 1. Patient Characteristics |
|---------------------------------|
| **Items** | **Description** | **n** | **Mean ± SD/Percent** |
| Age | Total | 28 | 51.11 ± 10.14 |
| Gender | Male | 22 | 78.57% |
| | Female | 6 | 21.43% |
| Eye | Right | 14 | 50% |
| | Left | 14 | 50% |
| Cause of trauma | Metal | 10 | 35.71% |
| | Fist | 5 | 17.86% |
| | Wood | 4 | 14.29% |
| | Traffic accident | 4 | 14.29% |
| | Plastic | 2 | 7.14% |
| | Stone | 1 | 3.57% |
| | Grass | 1 | 3.57% |
| | Firecracker | 1 | 3.57% |

| Table 2. Postoperative BCVA and IOP Compared With Preoperative Data |
|---------------------------------------------------------------|
| **Items** | **Total n** | **Preoperative** | **Postoperative** |
| | **NLP** | **LP** | **HM** | **χ² Value** | **P** | **NLP** | **LP** | **HM** | **χ² Value** | **P** |
| Preoperative | 28 | 14 | 11 | 3 | 1.55 | 0.21 | 7.01±2.43 | 3.03 | 0.0054 |
| Postoperative | 28 | 11 | 10 | 7 | 8.54±2.93 | 3.03 | 0.0054 |

IOP, intraocular pressure.
implanted successfully in all cases in our study, and there was no massive bleeding or FCVB rupture during the operation.

The most common postoperative complications are anterior chamber hemorrhage and inflammation, which can be completely cured after drug treatment. The average intraocular pressure after FCVB implantation was low, but the finger-measured intraocular pressure was Tn in this study, which may be caused by the use of different measuring instruments. According to the study of Bäurle et al, the IOP measured by GAT after PPV is on average 2.5 to 6 mmHg lower than the dynamic contour tonometer PASCAL (DCT) and even underestimated the IOP by 12 mmHg compared with DCT in one extreme case with gas endotamponade. In our study, there was a case of a shallow anterior chamber after surgery, which may have been related to the insufficient amount of viscoelastic substance injected into the anterior chamber during the operation. Although filtered clean air can also be used to fill the anterior chamber to maintain the intraocular pressure and depth of the anterior chamber, the study by Zhang et al showed that viscoelastic substances are better. Valve leakage and foreign body sensation can be avoided if the valve is made smaller in the future. Complications such as rejection, corneal degeneration, FCVB displacement, endophthalmitis, secondary glaucoma, silicone oil emulsification, and strabismus did not occur during the follow-up period in this study, which indicates that it is safe for FCVB implantation and is similar to previous research results.

Our research found that patients with FCVB implantation were highly satisfied. According to patient experience and recent research, the first and most important reason is due to a good or acceptable self-confidence and maintain healthy social emotions. Second, conventional complex retinal detachment repair with silicone oil may result in recurrent retinal detachment or silicone oil dependence, which ultimately leads to multiple surgeries, and the patient will suffer from physical, mental, and financial burdens. The FCVB can help patients avoid these burdens. In addition, because there is no need for a long-term prone position, patients can have good rest and return to work earlier, and their families do not need to take care of them all the time, which will bring more positive and optimistic attitudes in daily life and work. Interestingly, the FCVB can be used not only as a vitreous substitute but also as a drug delivery system to treat or prevent diseases, such as endophthalmitis and proliferative vitreoretinopathy. If the price drops to the level of intraocular lenses, the FCVB may become popular.

In summary, FCVB implantation for complicated retinal detachment caused by severe ocular trauma is effective and safe, and it can also eliminate psychological barriers, improve patient satisfaction, and allow patients to face life positively and optimistically.

**Key words:** foldable capsular vitreous body, complicated retinal detachment, ocular trauma, vitrectomy.

### Table 3. Postoperative Patient Satisfaction Compared With Preoperative Data

| Items                | Total Value | Preoperative | Postoperative |
|----------------------|-------------|--------------|---------------|
|                      | n | 0 | 1 | 2 | 3 |χ² | P |
| Preoperative         | 28 | 9 | 17 | 2 | 0 | 17.56 | <0.0001 |
| Postoperative        | 28 | 1 | 11 | 14 | 2 | |

*Feel dissatisfied as 0, feel satisfied sometime as 1, feel satisfied most of the time as 2, feel satisfied all the time as 3.*

---

**References**

1. Jac-Okerere CC, Jac-Okerere CA, Ezegwui IR, Umeh RE. Current pattern of ocular trauma as seen in tertiary institutions in south-eastern Nigeria. BMC Ophthalmol 2021;21:420.
2. Abdelazeem K, Al-Hussaini AK, El-Sebaity DM, Kedwany SM. Epidemiology, etiologies, and complications of playtime open globe injuries in children. J Pediatr Ophthalmol Strabismus 2021;58:385–389.
3. Khatri A, Shrestha SM, Kuhn F, et al. Ophthalmic Trauma Correlation Matrix (OTCM): a potential novel tool for evaluation of concomitant ocular tissue damage in open globe injuries. Graefes Arch Clin Exp Ophthalmol 2022;260:1773–1778.
4. Valentin-Bravo FJ, García-Onrubia L, Andrés-Iglesias C, et al. Complications associated with the use of silicone oil in vitreoretinal surgery: a systemic review and meta-analysis. Acta Ophthalmol 2021. Epub ahead of print.
5. Gao QY, Fu Y, Hui YN. Vitreous substitutes: challenges and directions. Int J Ophthalmol 2015;8:437–440.
6. Liu N, Kang L, Yu X, et al. Preliminary clinical application of foldable capsular vitreous body in severe silicone oil-dependent eyes. Ann Palliat Med 2021;10:10922–10929.
7. Feibel RM, Blodi CF, Paul A, Cibis, MD: a pioneer of modern vitreoretinal surgery. JAMA Ophthalmol 2013;131:1077–1082.
8. Bonfilgio V, Ortisi E, Nebbioso M, et al. Optical coherence tomography angiography evaluation of peripapillary microvascular changes after rhegmatogenous retinal detachment repair. Retina 2021;41:2540–2548.
9. Coman Cernat CC, Patoni Popescu SI, Malita D, et al. Endothelial corneal cell damage after pars plana vitrectomy: analogy of different intraocular tamponades. Rom J Ophthalmol 2021;65:141–149.
10. Jonas JB, Knorr HL, Rank RM, Budde WM. Retinal reattachment after removal of intraocular silicone oil tamponade. Br J Ophthalmol 2001;85:1203–1207.
11. Pettenkofer M, Chehaibou I, Pole C, et al. Epiretinal proliferation after rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol 2022;260:1509–1516.
12. Raczyńska D, Mitrosz K, Raczyńska K, Glasner L. The influence of silicone oil on the ganglion cell complex after pars plana vitrectomy for rhegmatogenous retinal detachment. Curr Pharm Des 2018;24:3476–3493.

13. Sugiura T, Kaji Y, Tanaka Y. Anatomy of the ciliary sulcus and the optimum site of needle passage for intraocular lens suture fixation in the living eye. J Cataract Refract Surg 2018;44:1247–1253.

14. Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve. Eye (Lond) 2008;22:461–468.

15. Liu Y, Jiang Z, Gao Q, et al. Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties. Artif Organs 2010;34:836–845.

16. Zhang B, Li C, Jia Y, et al. A pilot clinical study of treating rhegmatogenous retinal detachment by silicone rubber balloon scleral buckling. Retina 2020;40:1918–1928.

17. Schwartz SG, Flynn HW Jr, Mieler WF. Update on retinal detachment surgery. Curr Opin Ophthalmol 2013;24:255–261.

18. Chen S, Tian M, Zhang L, et al. Reattachment after foldable capsular vitreous body implantation in severe retinal detachment eyes. Transl Vis Sci Technol 2021;10:8.

19. Zhang X, Tian X, Zhang B, et al. Study on the effectiveness and safety of foldable capsular vitreous body implantation. BMC Ophthalmol 2019;19:260.

20. Lin X, Sun X, Wang Z, et al. Three-year efficacy and safety of a silicone oil-filled foldable-capsular-vitreous-body in three cases of severe retinal detachment. Transl Vis Sci Technol 2016;5:2.

21. Lin X, Ge J, Gao Q, et al. Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment. Invest Ophthalmol Vis Sci 2011;52:374–381.

22. Lin X, Wang Z, Jiang Z, et al. Preliminary efficacy and safety of a silicone oil-filled foldable capsular vitreous body in the treatment of severe retinal detachment. Retina 2012;32:729–741.

23. Chen H, Feng S, Liu Y, et al. Functional evaluation of a novel vitreous substitute using polyethylene glycol sols injected into a foldable capsular vitreous body. J Biomed Mater Res A 2013;101:2538–2547.

24. Yang W, Yuan Y, Zong Y, et al. Preliminary study on retinal vascular and oxygen-related changes after long-term silicone oil and foldable capsular vitreous body tamponade. Sci Rep 2014;4:5272.

25. Wang F, Gao Q, Lin X, et al. Comprehensive analysis of inflammatory immune mediators of the intraocular fluid aspirated from the foldable capsular vitreous body filled-eyes. PLOS One 2012;7:e46384.

26. Bäurle S, Viestenz A, Seitz B, Viestenz A. Intraocular pressure elevation after vitrectomy-Goldmann applanation tonometry measures lower intraocular pressure than dynamic contour tonometry. Ophthalmologe 2022;119:71–76.

27. Zhang Z, Liu S, Xie F, et al. Comparison of viscoelastic substance injection versus air filling in the anterior chamber during foldable capsular vitreous body (FCVB) implant surgery: a prospective randomized controlled trial. Adv Ther 2021;38:4859–4871.

28. Zhang C, Xiao R, Wang A, Zhao Z. Silicone oil-filled foldable capsular vitreous body versus silicone oil endotamponade for treatment of no light perception after severe ocular trauma. Retina 2022;42:553–560.

29. Wang T, Huang X, Gao Q, et al. A preliminary study to treat severe endophthalmitis via a foldable capsular vitreous body with sustained levofloxacin release in rabbits. Invest Ophthalmol Vis Sci 2013;54:804–812.

30. Zheng H, Wang Z, Wang P, et al. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo. Graefes Arch Clin Exp Ophthalmol 2012;250:751–759.